The Pathfinding Partnerships Award from CO-LABS recognizes impactful, collaborative research projects organized by four or more research entities, including federal labs, in Colorado. This year, the Wildfire Research (WiRē) team received this award for their support of evidence-based community wildfire education to help communities live with wildfire. 

Western Fisheries Research Center scientists are studying the impacts of increased artificial light at night (ALAN) on aquatic ecosystems.  Here's an overview with recent pictures from the field!

President Biden signed a memorial bill to recognize the victims of the 2016 Pulse nightclub shooting and offered his condolences to people who are awaiting news on their loved ones in the wake of the deadly Surfside, Fla., partial condo collapse.

Biden — who was vice president when a 29-year-old man killed 49 people and wounded 53 more in the nightclub mass shooting — signed the bill to enshrine a monument to the dozens killed in the Latin Night massacre.

The shooting occurred at a gay nightclub in Orlando, Fla., in June 2016. The month of June is celebrated annually as LGBTQ Pride Month in the United States.

"May a president never have to sign another monument like this," Biden said.

Biden also offered his thoughts to the victims and loved ones of those affected by the catastrophic collapse this week of a Miami-Dade County condo. Authorities say four people have been declared dead and an additional 159 are considered missing in the rubble.

"I just want to say, I've spoken to Gov. [Ron] DeSantis, and we've provided all the help that they have, they need," Biden said. "We sent the best people from FEMA down there. We're going to stay with them."

This content is from Southern California Public Radio. View the original story at SCPR.org.

According to one new account of the Trump presidency, even telling the story of President Trump's Covid diagnosis was difficult due to the chaos in the white house. Here, Trump removes his protective mask after being discharged from the Walter Reed National Military Medical Center with Covid-19.; Credit: Bloomberg/Bloomberg via Getty Images

When the Wall Street Journal's Michael Bender wrote his book about Donald Trump's 2020 defeat, one section stuck out as particularly difficult: telling the story of what Bender dubbed "Hell Week-And-A-Half."​

"It was the ten days in 2020 that started with the super spreader event in the Rose Garden, included the Trump's disastrous debate with Joe Biden in Cleveland, and then Trump himself obviously testing positive for COVID a few days later," Bender said.

It's not just that it was a lot to fold together; it's that simply figuring out what happened was maddening.​

"How early he tested positive, how sick he was during that time — I mean, these are serious questions with national security implications that very few people knew or had firsthand knowledge of, and I had competing versions from senior officials, serious people who all were telling me different versions of that story," he said.

Bender's Frankly, We Did Win This Election is one of many books trying to pull order from Trump's chaos, and that struggle to discern the truth, he explains, is itself emblematic of the Trump administration.​

"The deception wasn't just with the public. It was literally from person to person inside the West Wing," he said. "And that's the story — not necessarily worrying about exactly what happened, which will have to come out at some later point, if it ever does."

Former officials are judging Trump's election lies and pandemic response poorly

Judging from the excerpts that have been released, this first wave of post-Trump-presidency books is filled with behind-closed-doors details — like, for example, how gravely ill Trump was with COVID-19, or former Attorney General William Barr's blunt assessment about Trump's claims of a rigged election: "​My suspicion all the way along was that there was nothing there. That it was all bulls***," as ABC's Jonathan Karl recounts.

But the challenge of recounting this chapter of American history is not just about recounting news-making moments — the racist statements, the allegations of sexual assault, the impeachments — but making sense of it.​

Yasmeen Abutaleb, who coauthored the forthcoming Nightmare Scenario with her Washington Post colleague Damian Paletta, agreed that it was hard to discern the truth from dozens of conflicting stories from within the White House.

But that made it all the more striking when they did find consensus on the Trump White House's coronavirus response. "Of the more than 180 people we spoke to, there wasn't a single one who defended the collective response," she said.

Writing this book, she added, allowed her and Paletta to come away with a clearer assessment of the Trump White House's pandemic response than they gleaned from their day-to-day coverage last year.

"Coronavirus was going to be a challenge no matter who was in charge," she said. "But when we looked at the number of opportunities there were to turn the response around, many of which we didn't know about at the time or couldn't learn it at the time, I think we were shocked at the number of opportunities there were and how they weren't taken."

In addition to the challenge of telling complete, ordered stories of a chaotic presidency, there is also the challenge of placing that presidency into historical context, says Princeton presidential historian Julian Zelizer. He's working with a team of historians to pull together a history of the Trump administration.

"Why did America's political system have room for so much chaos over a four year period? Which is this big puzzle I don't think everyone's totally grappled with," he said.

It's not just journalists and historians. Trump-administration insiders will try to explain their place in history. That's according to Keith Urbahn, a co-founder of Javelin, a literary agency that represented Bender, former UN ambassador John Bolton, and former FBI director James Comey, with more to come.​

"I think it does require for people who worked in the Trump presidency to wrestle with some of the moral compromises that they had to make by serving in that administration," he said.

Post-Trump chaos is rippling through the publishing world

Writing the history of a leaky, live-tweeted presidency has been unusual for a variety of additional reasons. There's book industry tumult — Simon and Schuster employees protested the publishing giant over printing former Vice President Mike Pence's book.

In addition, Trump could still run for president again, which may be why he has given at least 22 book interviews, Axios recently reported. (He has also said he is writing the "book of all books," though some major publishers are hesitant about publishing it, Politico has reported.)

The Trump era was also unusual for the book industry in another way.

"We can honestly say that the four years of the Trump administration were four of the strongest years cumulatively for political books since we've been tracking books, which started in 2001," said Kristen McLean, executive director and industry analyst at market research firm NPD.

Now, however, those sales moving back towards a pre-Trump normal — political book sales are down 60% from the second half of 2020, McLean said.

But that doesn't mean interest will disappear, according to Javelin co-founder Matt Latimer.​

"For example, next year there are a dozen or more books coming out about President Nixon," he said. "I mean, I think long after we're all gone, people are going to be trying to figure out what the hell this was all about."

It's been 47 years since Nixon resigned. By that same math, we'll be reading new Trump books into the late 2060s — and probably beyond.

This content is from Southern California Public Radio. View the original story at SCPR.org.

ANTHONY RAMOS as Usnavi in Warner Bros. Pictures’ “IN THE HEIGHTS.”; Credit: Macall Polay/Warner Bros. Pictures’

Larry Mantle and KPCC film critics Angie Han, Andy Klein, Tim Cogshell and Charles Solomon review this weekend’s new movie releases on streaming and on demand platforms.

• "In the Heights," on wide release & HBO Max

• "Holler," at Laemmle’s Monica Film Center (Santa Monica), Laemmle’s Playhouse 7 (Pasadena); VOD (including FandangoNow, Google Play & VUDU)

• "A Perfect Enemy," in select theaters (check your local listings)

• "Wish Dragon," on Netflix

• "Sublet," at Laemmle theaters (Playhouse 7, Town Center 5, Royal); Laemmle’s Virtual Cinema on June 18; VOD on July 9

• "The Hitman's Wife's Bodyguard," on wide release June 16 (they also have select earlier showtimes June 11 & 12)

• "Censor," Laemmle’s Glendale, Alamo Drafthouse Cinema (DTLA) and Landmark Westwood; VOD (including iTunes, Amazon Prime Video, YouTube) on June 18

• "La Dosis (The Dose)," on VOD/Digital (including iTunes & FandangoNow)

• "Revolution Rent," on HBO Max on June 15

• "The Misfits," In select theaters (including Universal Cinema AMC and Cinemark 18 & XD); VOD/Digital (including Vudu, Google Play) on June 15 

• "Take Me Somewhere Nice," at Laemmle’s Virtual Cinema 

• "Queen Bees," at Laemmle’s Virtual Cinema, Laemmle’s Theaters (including Glendale, Playhouse 7, Monica Film Center, Newhall & Town Center 5); VOD (including Vudu, Amazon Prime Video & Apple TV)

Our FilmWeek critics have been curating personal lists of their favorite TV shows and movies to binge-watch during self-quarantine. You can see recommendations from each of the critics and where you can watch them here.

Guests:

Tim Cogshell, film critic for KPCC, Alt-Film Guide and CineGods.com; he tweets @CinemaInMind

Andy Klein, KPCC film critic

Angie Han, film critic for KPCC and deputy entertainment editor at Mashable; she tweets @ajhan

Charles Solomon, film critic for KPCC, Animation Scoop and Animation Magazine

This content is from Southern California Public Radio. View the original story at SCPR.org.

Edgar Wright attends the 55th Annual International Cinematographers Guild Publicists Awards at The Beverly Hilton Hotel on March 2, 2018 in Beverly Hills, California.; Credit: Tommaso Boddi/Getty Images

The joke about Sparks — if you’ve even heard of them — is that it’s the best British band to come out of America. That confusion is why Edgar Wright, the director of “Baby Driver” and “Shaun of the Dead,” wanted to make his first documentary about the group, headed by brothers Ron and Russell Mael. Quite simply, Wright was tired of explaining who the band was and why he loves them. His documentary, called “The Sparks Brothers,” premiered at this year’s Sundance Film Festival. John Horn talked with Wright after its January premiere about his personal connection to the band, how he connected with the brother, the editing process of the documentary and more. The film is in theaters now.

With guest host John Horn

Guest: 

Edgar Wright, director of the new documentary “The Sparks Brothers;” he tweets @edgarwright

This content is from Southern California Public Radio. View the original story at SCPR.org.

Giant Mining Corp. (CSE: BFG; OTC:BFGFF; FWB:YW5) announced the expansion of its surface exploration program at the Majuba Hill copper-silver deposit in Pershing County, Nevada. Read more to learn about the promising high-grade copper findings and the project's potential impact on the EV and renewable energy sectors.

Stillwater Critical Minerals Corp. (PGE:TSX.V; PGEZF:OTCQB; J0G:FSE) has announced new assay results from its ongoing resource expansion drilling at the Stillwater West PGE-Ni-Cu-Co + Au project. Read more for detailed insights into the high-grade rhodium intercepts and resource expansion potential.

Full Text:

Earth's magnetic field seems steady and true -- reliable enough to navigate by. Yet, largely hidden from daily life, the field drifts, waxes and wanes. The magnetic North Pole is currently shifting toward Siberia, forcing the Global Positioning System that underlies modern navigation to update its software sooner than expected. Every several hundred thousand years, the magnetic field dramatically shifts and reverses its polarity. Magnetic north flips to the geographic South Pole and, eventually, back again. This reversal has happened countless times over Earth's history, but scientists' understanding of why and how the field reverses is limited. The researchers find that the most recent field reversal 770,000 years ago took at least 22,000 years to complete, several times longer than previously thought. The results call into question controversial findings that some reversals could occur within a human lifetime.

Image credit: Brad Singer

Full Text:

National Science Foundation (NSF)-funded researchers from North Carolina State and Elon universities have developed a technique that allows them to remotely control the movement of soft robots, lock them into position for as long as needed and later reconfigure the robots into new shapes. The technique relies on light and magnetic fields. "By engineering the properties of the material, we can control the soft robot's movement remotely; we can get it to hold a given shape; we can then return the robot to its original shape or further modify its movement; and we can do this repeatedly. All of those things are valuable, in terms of this technology's utility in biomedical or aerospace applications," says Joe Tracy, a professor of materials science and engineering at NC State and corresponding author of a paper on the work. In experimental testing, the researchers demonstrated that the soft robots could be used to form "grabbers" for lifting and transporting objects. The soft robots could also be used as cantilevers or folded into "flowers" with petals that bend in different directions. "We are not limited to binary configurations, such as a grabber being either open or closed," says Jessica Liu, first author of the paper and a Ph.D. student at NC State. "We can control the light to ensure that a robot will hold its shape at any point."

Image credit: Jessica A.C. Liu

Source: Ed Arce 10/09/2024

H.C. Wainwright & Co. analysts Ed Arce and Thomas Yip, in a research report published on October 9, 2024, maintained a Buy rating on Unicycive Therapeutics Inc. (UNCY:NASDAQ) with a price target of US$2.50. The report follows Unicycive's announcement of the successful completion of the Phase 1 study for UNI-494 in healthy volunteers.

Arce and Yip highlighted the significance of the study results, stating, "UNI-494 showed rapid metabolism, enabling the expected release of nicorandil and its linker." They added, "Importantly, PK results collected in the study showed fast absorption of UNI-494, with rapid metabolism leading to the expected release of nicorandil and its linker."

The analysts noted the safety profile of UNI-494, commenting, "UNI-494 was generally safe and well-tolerated; headache was the most common adverse event (AE), and all AEs were mild with no serious adverse events (SAEs) or AEs leading to withdrawal in Part 1."

Regarding Unicycive's strategic plans, the analysts stated, "Management plans to request a meeting with the FDA by year-end 2024 to review these Phase 1 results and discuss the design of a potential Phase 2 study in patients with acute kidney injury (AKI)."

The report also highlighted the pending milestone for Unicycive's other product candidate, Oxylanthanum Carbonate (OLC), noting, "We await the FDA's formal acceptance of the NDA for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis (we expect by November 2) with a PDUFA date assignment to further narrow OLC's potential approval timing."

H.C. Wainwright & Co.'s valuation methodology for Unicycive is based on a risk-adjusted Net Present Value (rNPV) model. The analysts explained, "We employ a rNPV valuation model to estimate the value of UNCY shares and arrive at our US$2.50 PT based on: (1) about US$2.30 per share for royalties on net sales of OLC in the U.S. and EU (85% PoS, US$149.1M global peak revenue in 2034); and (2) about US$0.25 per share for royalties on net sales of UNI-494 in the U.S. and EU for AKI (20% PoS; US$195M global peak revenue in 2036)."

They added, "In our valuation model, we employ a 14.5% discount rate, which we believe adequately reflects the overall risks of the Unicycive development pipeline. We conservatively assume zero terminal value after the end of the market exclusivity period that runs through 2037."

The analysts also outlined several risk factors, including regulatory, commercialization, market, intellectual property, and funding risks.

In conclusion, H.C. Wainwright & Co.'s maintenance of a Buy rating and US$2.50 price target reflects a positive outlook on Unicycive Therapeutics' potential in developing UNI-494 for AKI and OLC for hyperphosphatemia. The share price at the time of the report of US$0.36 represents a potential return of approximately 594% to the analysts' target price, highlighting the upside potential if the company's clinical development and regulatory plans prove successful.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Unicycive Therapeutics Inc., October 9, 2024

Important Disclaimers This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Ed Arce and Thomas Yip , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Unicycive Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Unicycive Therapeutics, Inc..

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The Firm or its affiliates did not receive compensation from Unicycive Therapeutics, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Unicycive Therapeutics, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: UNCY:NASDAQ, )

Source: Andrew Fein 10/23/2024

H.C. Wainwright & Co. analysts Andrew S. Fein, Matthew Caufield, Dr. Andres Y. Maldonado, and Dr. Ananda Ghosh, in a research report published on October 23, 2024, maintained a Buy rating on DBV Technologies SA (DBVT:NASDAQ) while raising their price target to US$7.00 from US$5.00. The report follows DBV's announcement of regulatory clarity regarding the path forward for its Viaskin Peanut patch.

The analysts highlighted the significance of the FDA agreement, stating, "DBV Technologies has reached an agreement with the FDA regarding the regulatory pathway for the Viaskin Peanut patch in toddlers aged one to three, under the Accelerated Approval pathway."

Regarding the company's development timeline, the analysts noted, "The Biologics License Application (BLA) submission for Viaskin Peanut in this age group is expected to be supported by positive efficacy and safety data from DBV's completed EPITOPE Phase 3 study, as well as additional safety data from the upcoming six-month COMFORT Toddlers supplemental safety study, which is expected to begin in 2Q25."

The report emphasized the strength of DBV's regulatory position, stating, "The FDA has stated that DBV has already satisfied two of the three criteria: the product treats a serious condition, and the product candidate provides a meaningful advantage over available therapies."

The analysts also highlighted progress in Europe, noting, "The EMA confirmed that the successfully completed EPITOPE Phase 3 efficacy and safety trial in the one to three-year-old population, along with positive results from the VITESSE study in the four to seven-year-old population, and a new safety study using the modified circular patch in one to three-year-olds, could support an MAA for the one to seven-year-old indication with the modified patch."

The analysts' valuation methodology for DBV Technologies is based on a composite approach. They explained, "Our US$7 price target is based on an equally weighted composite of: (a) US$5.10/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of US$5.13 discounted back to FY24 at 35%; and (b) an NPV of US$8.52/share with a 13% discount rate and 1% growth rate."

The report included commercial projections, with the analysts stating, "We continue to model initial approval in 2027, with projected initial sales of US$17.5M, growing to US$1,182.8M by 2034."

The analysts also outlined several risk factors, including potential clinical study failures, regulatory approval challenges, and market size uncertainties.

In conclusion, H.C. Wainwright & Co.'s increased price target to US$7 reflects growing confidence in DBV Technologies' regulatory pathway for the Viaskin Peanut patch. The share price at the time of the report of US$0.70 represents a potential return of approximately 900% to the analysts' target price, highlighting the significant upside potential if the company successfully navigates the regulatory process and commercializes its product.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co. DBV Technologies S.A., October 23, 2024

Important Disclaimers This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Andrew S. Fein, Matthew Caufield, Andres Y. Maldonado, PhD and Ananda Ghosh, PhD , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of DBV Technologies S.A. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of DBV Technologies S.A.

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The firm or its affiliates received compensation from DBV Technologies S.A. for non-investment banking services in the previous 12 months. The Firm or its affiliates did not receive compensation from DBV Technologies S.A. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in DBV Technologies S.A. as of the date of this research report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: DBVT:NASDAQ, )

Source: Streetwise Reports 10/31/2024

Healthcare artificial intelligence (AI) company Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) announced that it has closed a non-brokered private placement for aggregate gross proceeds of CA$1.95 million.

A total of 2,138,766 special warrants of the company were offered at CA$0.75 per special warrant with proceeds of CA$1.6 million. The company also said 466,666 units of the company were offered at CA$0.75 per unit for proceeds of CA$349,999.50.

The company said it intends to use the proceeds for working capital purposes.

"We are very encouraged by the support from our investors with their overwhelming response to the financing and the subsequent over-subscription," Chief Executive Officer Dr. Essam Hamza said. "This money will help expedite our aggressive growth plans over the next year."

Technical Analyst Clive Maund noted on October 9* that the outlook for the company is "outstandingly bright" because it has "positioned itself to revolutionize the healthcare industry using AI and advanced machine learning technologies."

The company "is set to transform the current archaic system so that no longer do patients have to sit for hours in waiting rooms to see a doctor or doctors, and doctors and other healthcare professionals have to suffer a crushing burden of often unnecessary patient visits and tedious repetitive bureaucracy," he wrote. "Treatment AI's platform will take care of most of it."

Healthcare Professionals Worldwide Contribute to AI Engine

Treatment.com AI said it is a company utilizing AI and best clinical practices with a goal to positively improve the healthcare sector and impact current inefficiencies and challenges.

With the input of hundreds of healthcare professionals globally, Treatment.com AI said it has built a comprehensive, personalized healthcare AI engine called the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM is designed to provide tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), X-rays, and billing codes.

According to the company, the GLM will help healthcare professionals (doctors, nurses, and pharmacists) reduce administrative burdens, creating more time for face-to-face patient appointments.

"AI is set to expedite and streamline the healthcare industry, making it vastly more efficient for the benefit of both healthcare professionals and patients," Maund noted.

The Catalyst: A 'Profound Transformation' in the Industry

AI has an important role to play in the healthcare offerings of the future, a 2019 report from the National Center of Biomechanical Medicine listed in the National Library of Medicine said. "In the form of machine learning, it is the primary capability behind the development of precision medicine, widely agreed to be a sorely needed advance in care."

Healthcare organizations are increasingly turning to the technology to address both clinical and administrative challenges. The combination of generative AI, as noted by Appinventiv in September, and operational tools like those developed by Treatment.com AI are driving this transformation.

Generative AI is "catalyzing a profound transformation within the healthcare industry" by generating synthetic data, predicting patient outcomes, and optimizing treatment plans, all of which revolutionize clinical decision-making processes, Appinventiv reported. This aligns with Treatment.com AI's announced collaboration with SPRYT on September 17 whereby integrating SPRYT’s AI receptionist "Asa" with its GLM has the goal of enhancing patient access to healthcare while reducing administrative burdens.

A CBC report from September 16 said real-world applications of AI in healthcare are already showing promising results. Dr. Muhammad Mamdani, co-author of a study on the topic, expressed optimism about AI's ability to "complement clinicians' own judgment and lead to better outcomes for fragile patients."

According to a report by Markets and Markets, the global AI in healthcare market in total was valued at US$20.9 billion this year and will reach an estimated US$148.4 billion by 2029, a compound annual growth rate (CAGR) of 48.1%.

"The growth of AI in the healthcare market is driven by the generation of large and complex healthcare datasets, the pressing need to reduce healthcare costs, improving computing power and declining hardware costs, and the rising number of partnerships and collaborations among different domains in the healthcare sector, and growing need for improvised healthcare services due to imbalance between healthcare workforce and patients," the report said.

Analyst: A 'Genuine Breakout Soon' for Stock

Maund said its stock charts are also looking "very positive indeed" for the company.

Of particular note is the big upleg late in June and early in July on persistent heavy volume, which broke the price clear above the May high and drove volume indicators steeply higher," the analyst noted. [OWNERSHIP_CHART-10594]

"This is very bullish price/volume action, especially as the volume indicators have not just held up but have actually advanced as the price has reacted back in a normal manner from the early July high to arrive at a support level where it has stabilized above the 200-day moving average in readiness for renewed advance, so the correction looks like a large bull Pennant that, as it is now closing up, promises renewed advance soon," continued Maund, who said holders should stay long and rated the stock a Strong Buy that "is thought worth going overweight on."

"The June-July rally must be classed as a 'preliminary' breakout," he noted. "But that said, the exceptionally bullish price/volume action of recent months does promise a genuine breakout soon that looks set to lead to a sustained and substantial uptrend."

Ownership and Share Structure

According to Sedi.ca, insiders own approximately 8% of Treatment.com AI. Retail investors own the remaining 92%.

The company has 48.84 million outstanding common shares and has 41.3 million free float traded shares.

As of October 31, the market cap is approximately CA$31.75 million. Over the past 52 weeks, the company traded between CA$0.355 and CA$1.11 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Treatment.com AI has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

* Disclosure for quotes from the Clive Maund source October 9, 2024

1. For the quote (sourced on October 9, 2024), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$1,500.
2. Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing the article quoted. Maund received his UK Technical Analysts’ Diploma in 1989. The recommendations and opinions expressed in the article accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed.

Clivemaund.com Disclosures

The quoted article represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be only be construed as a recommendation or solicitation to buy and sell securities.

( Companies Mentioned: TRUE:CSE; TREIF:OTCMKTS;939:FRA, )

On-Demand Webinar > Watch Now! SPONSORED BY: TripwireWatch this FREE on-demand webinar to learn how to overcome the top 5 compliance challenges keeping IT directors awake at night! Watch Now! Overc...

Aero Energy Ltd. (AERO:TSXV; AAUGF:OTC; UU3:FRA) has announced significant advancements at its Murmac and Sun Dog uranium projects in Northern Saskatchewan. Read how this and a CA$2.5-million non-brokered private placement aim the company towards further exploration.

The pandemic has once again felled Burning Man. Some burners still plan to gather for informal events on the dusty Black Rock Desert Playa this summer.; Credit: Bernard Friel/Education Images/Universal Images Group via Getty Images

And so it goes: Burning Man 2021 is canceled. It's the second year in a row, the popular arts festival won't be held in Nevada's Black Rock Desert due to the pandemic.

"We have decided to set our sights on Black Rock City 2022," event officials announced in a blog post on Tuesday. In a frequently-asked-questions section, organizers added: "We've heard from many who don't feel ready to come to Black Rock City. While we're confident in our ability to get a permit and to safeguard public health, we know that co-creating Black Rock City in 2021 would put tremendous strain on our community while we are still ironing out uncertainty."

Many would-be attendees praised the decision in comments on the Burning Man website and on social media as a safe one; others are anxiously anticipating a bigger and better 2022 Burn.

But the cancellation has put many people in the event's host community at ease.

Wary of a trend of rising coronavirus cases in some parts of the region, Washoe County's district health officer Kevin Dick said "the right call was made," in order to lower the risk of spreading infection.

"The event draws thousands of people from all over the world," Dick said in an email. "We are seeing large outbreaks of COVID-19 occurring in a number of countries, areas where very contagious COVID-19 variants of concern are prevalent and where low rates of vaccination are occurring."

The head of a local Paiute tribe is also feeling less burdened knowing there won't be the annual pilgrimage. The main highway to get to the Black Rock Desert playa, which normally draws tens of thousands of people to the summer event, cuts through tribal lands.

"For us it is a sigh of relief," said Janet Davis, chairwoman of the Pyramid Lake Paiute Tribe.

Although the event — which brings in about $63 million to the state annually — gives the tribal community a welcome financial boost, Davis said.

"We don't know who's vaccinated and who's not," she said. "We've been trying to keep our reservation safe and that happening was too soon for us to open."

As with last year, the organization will offer virtual programming during Burn Week, from Aug. 29 through Sept. 7, an experience they say drew 165,000 participants in 2020.

In response to a request for more details on the reasons for the cancellation, Burning Man organizers declined to comment further. Earlier this month, though, CEO Marian Goodell said the organization was "weighing the gravity" of implementing a vaccination requirement that she said challenged "radical inclusion," one of the group's 10 principles.

Still, for many burners, the news won't extinguish their plans to trek to the desert in droves. Just like last year, revelers are preparing to hold unofficial gatherings on public land in place of the annual event.

Last summer, those events — the so-called "rogue" and "free" burns or, unmistakably, "Not Burning Man" — drew an estimated 3,000 people to Black Rock Desert during the time Burning Man is normally held, according to the Bureau of Land Management, the federal agency that approves the organization's permits each year.

Kevin Jervis, one such attendee who now lives in Gerlach — a tiny desert town near the event site — welcomed this year's cancellation.

He called it "more of a relief than anything. ... A lot of us liked it better the way it happened last year."

During the informal festivities, Jervis spent a few days between the playa and its outskirts. He said he and his fellow burners felt like it represented the festival's freewheeling roots.

"I've had friends that have been going since '94 and they said it was a lot more like it used to be. We didn't have to go by regulations," he said. "We could have guns, dogs ... it was a lot freer."

Even before the pandemic, burners increasingly saw an annual gathering under siege.

Event-goers who adhere to Burning Man's counterculture beginnings say the festival's explosion in popularity in the past decade has welcomed a host of bad actors who trash the desert and surrounding communities and disregard the event's founding principles, including "decommodification" and the eco-friendly philosophy of "leave no trace."

Some of those perceived threats come from festival officials themselves, he said. A ticket to the main event alone cost over $400 in 2019 — a financial hurdle critics say goes against another tenet long espoused, that "everyone is invited."

"People that have never been before came out last year because they either couldn't get a ticket other years or they were just kind of curious. Or they didn't have the money to go to the actual Burn," said Jervis.

As for the Pyramid Lake Paiute community, with the reservation largely closed during that period last year, Davis said, "we really didn't see the impact" from a public health standpoint.

"You're not talking about 65 — 75,000 people." While there was more traffic, she said, "they moseyed on through and moseyed on out."

In the years leading up to the pandemic, BLM had been cracking down on the event's growth. Were the festival to return this year, Burning Man organizers said they would have had to meet a population cap of 69,000, down from its 80,000 limit for previous events.

Jervis says he won't miss what he describes as organizers' leniency toward "elites" who set up VIP areas at their camps and hire out to construct their art creations instead of making their own.

"A lot of people have gotten sick of what Burning Man's kind of become," he said.

Even if this year was a go, he said, burners would still be setting up their own Burning Man-adjacent happenings.

Following the announcement of the event's cancellation, people are taking to Facebook groups to reminisce about last year's unsanctioned burns and discuss preparations for their own this summer.

"So it seems that as of today there isn't going to be an official [Burning Man Ceremony] this year," James Zapata wrote. "So who's joining me in the dust?"

This content is from Southern California Public Radio. View the original story at SCPR.org.

Live-event spaces, like the Sound Nightclub in Los Angeles, have been waiting months for emergency relief.; Credit: Mario Tama/Getty Images

Owners of live-music venues, theaters, museums and other businesses covered under the Shuttered Venue Operators Grant, or SVOG, can expect to see money by the end of May. This is according to an update from the Small Business Administration, which has been handling the SVOG program's bumpy rollout.

An SBA spokesperson said in an email that since the portal to apply for these grants opened a week ago, 10,300 applications have been submitted (another 12,000 have been started but not completed). The vast majority of those applications were from "Live venue operators or promoters," followed by performing arts organizations and then movie theaters.

The SBA has been reviewing applications and said in a statement that "applicants will receive notice of awards this month," with disbursement by the end of May if the applicant responds in a "timely manner to the notice of award."

The SVOG program is a $16 billion emergency relief program that then-President Donald Trump signed into law in late December 2020. It was a bipartisan effort to get aid money to struggling music venues and other arts and live-event spaces that have been hit hard by the coronavirus struggles. But for an emergency relief program, it has taken months to get money in the hands of business owners holding off landlords, insurance companies and other creditors. Those owners spent early 2021 waiting on an official announcement of when they could apply for the grant money while compiling any documents and paperwork they thought they might need. Then once the application site was up and running, it crashed and was closed.

Even as large festivals roll out throughout the U.S. and bands announce tours for later in the year, many small live-event spaces are still at risk of closing. The National Independent Venue Association, one of the most vocal groups lobbying for support for live-music venues, has long stated that 90% of its members would be forced to close without any aid — which would hurt nearby bars, restaurants and shops, not to mention the large apparatus that is the live touring-arts industry.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Dryden Gold Corp. (DRY:TSXV; DRYGF:OTCQB) has announced its participation in three significant mining investment conferences scheduled for November 2024. Read more about the company's plans to showcase major project updates and connect with global investors at these key events.

GoldMining Inc. (GOLD:TSX; GLDG:NYSE.American) released results from its ongoing 2024 auger drilling program at the Sao Jorge Project in the Tapajos gold district, Para State, Brazil. Read more about high-grade gold intercepts and new exploration targets at So Jorge as GoldMining extends its search in Tapajs.

People come to Catawba County’s web site for many reasons. One is for the information and data that they find there.  The site has always been rich in information about the county and services that are provided. In recent years, as more and more people wanted data in digital format, many datasets were moved to [...]

A tropical storm with 65-mile-an-hour winds is drenching Cuba, and is expected to reach Key West and the west coast of Florida within the next 48 hours.

The National Hurricane Center expects Tropical Storm Elsa to drop between 5 and 10 inches of rain on central and western Cuba, leading to significant flooding and mudslides. The storm probably will weaken somewhat as it crosses the island, but could strengthen again as it approaches Florida.

According to the Associated Press, Cuban officials evacuated 180,000 people as a precaution against the possibility of heavy flooding.

Most of those evacuated stayed at relatives' homes, others went to government shelters, and hundreds living in mountainous areas took refuge in caves prepared for emergencies. The storm had killed at least three people on other Caribbean islands before it reached Cuba

The National Weather Service says that the western coast of Florida, including Tampa Bay, can expect a storm surge that would lift water levels between two and four feet. Much of Florida could see heavy rainfall that could reach six inches in some places. The storm will then bring heavy rains to Georgia and the Carolinas later in the week.

Florida officials were worried that the storm could destabilize what was left of the condominium building that partially collapsed over a week ago. In order to avoid an uncontrolled collapse, they approved the demolition of the remaining portion of the building, which took place on Sunday night.

"The hurricane was coming, the potential for that building to fall on the pile with the victims in it was a tragic thought," Surfside Mayor Charles Burkett told NPR on Monday.

It's early in the hurricane season. The National Oceanic and Atmospheric Administration has predicted a busier-than-average Atlantic hurricane season, but it would be hard to top last year's, which set an all-time record with 30 named storms.

Tropical storms are fueled by warm water in the upper layers of the ocean, and ocean temperatures have been rising as heat is trapped by greenhouse gases.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Oil prices have whipsawed between concerns over supply as Western sanctions on Russian crude and products over the Ukraine war disrupt trade flows, and worries that central bank efforts to tame inflation may trigger a demand-destroying recession.

Two members of the Catawba County Board of Commissioners, Vice-Chair Lynn Lail and Commissioner Barbara Beatty joined UNC Charlotte officials and leaders from business and power industries to celebrate the start of construction on the University�s Energy Production and Infrastructure Center (EPIC). EPIC is a planned research endeavor between the University and private partners with the goal of expanding energy engineering and research within the region based on industry needs. The Catawba County EcoComplex will play an important role in EPIC through research partnership between Catawba County and UNC-Charlotte

The North Carolina Department of Transportation has released recommendations on widening of Highway 16 South in Catawba County (within the minutes of public meetings). Link to project maps: http://www.ncdot.org/doh/preconstruct/highway/roadway/hearingmaps_by_county/county/Catawba.html

Colonel Michael W. Gilchrist, Commander of the Highway Patrol, presented the awards to EMT Paramedic and Crew Chief Brad Harris and EMT Paramedic Eric Jones for their role in pulling a person from a burning vehicle.

Catawba County Home Health is empowering older adults to lower their risk of falling through a new service called Smart Moves.

County employees in the first Leadership Academy recently helped families in transition through a Family Care Center project.

Catawba County Board of Commissioners adopts resolution supporting citizen participation in government through elections in Catawba County.

A bold national initiative is needed to reduce the enormous health burden of sexually transmitted diseases (STDs) in the United States, according to a new report from a committee of the Institute of Medicine.

More targeted aircraft testing and simulation should be conducted to uncover design characteristics in new flight control systems that -- in rare circumstances -- may mislead pilots and result in unstable or dangerous flight conditions, says a new report by a National Research Council committee.

No justification currently exists for completely abandoning chemical pesticides, says a new report from the National Academies National Research Council.

Darkly colored, carotene-rich fruits and vegetables -- such as carrots, sweet potatoes, and broccoli -- provide the body with half as much vitamin A as previously thought.

To ensure that minority students who are poorly prepared for school are not assigned to special education for that reason, educators should be required to first provide them with high-quality instruction and social support in a general education classroom before making a determination that special education is needed.

High schools that successfully engage students in learning have many things in common.

The U.S. Environmental Protection Agencys standard for the maximum amount of fluoride allowed in drinking water -- 4 milligrams of fluoride per liter of water -- does not protect against adverse health effects.

There is sufficient evidence from tree rings, boreholes, retreating glaciers, and other proxies of past surface temperatures to say with a high level of confidence that the last few decades of the 20th century were warmer than any comparable period in the last 400 years, according to a new report from the National Research Council.

A growing amount of scientific evidence indicates that how much weight women gain during pregnancy and their starting weight at conception can affect their health and that of their babies, says a new report from the Institute of Medicine and the National Research Council.

A report released today by the National Research Council presents a new framework for K-12 science education that identifies the key scientific ideas and practices all students should learn by the end of high school.

A new report from the Institute of Medicine (IOM) recommends that eight preventive health services for women be added to the services that health plans will cover at no cost to patients under the Patient Protection and Affordable Care Act of 2010 (ACA).

Americas progress in arresting its obesity epidemic has been too slow, and the condition continues to erode productivity and cause millions to suffer from potentially debilitating and deadly chronic illnesses.

Hydraulic fracturing has a low risk for inducing earthquakes that can be felt by people, but underground injection of wastewater produced by hydraulic fracturing and other energy technologies has a higher risk of causing such earthquakes, says a new report from the National Research Council.

On average, Americans die sooner and experience higher rates of disease and injury than people in other high-income countries, says a new report from the National Research Council and Institute of Medicine.

Young athletes in the U.S. face a culture of resistance to reporting when they might have a concussion and to complying with treatment plans.

The analysis used by federal agencies to set standards for fuel economy and greenhouse gas emissions for new U.S. light-duty vehicles -- passenger cars and light trucks -- from 2017 to 2025 was thorough and of high caliber overall, says a new report from the National Research Council.

During the National Academy of Medicine (NAM) Annual Meeting, Leonard Rubenstein, Director of the Program on Human Rights, Health and Conflict (Center for Public Health and Human Rights) at Johns Hopkins Bloomberg School of Public Health, and Dr. Denis Mukwege, founder and medical director of Panzi Hospital in the DRC, spoke to NAM members about attacks against healthcare professionals globally and the importance of supporting the work of medical professionals in conflict zones.

Efforts to convert civilian research reactors from weapon-grade highly enriched uranium (HEU) to low enriched uranium (LEU) fuels are taking significantly longer than anticipated, says a congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine.

Potentially useful biomarker tests for molecularly targeted therapies are not being adopted appropriately into clinical practice because of a lack of common evidentiary standards necessary for regulatory, reimbursement, and treatment decisions, says a new report by the National Academies of Sciences, Engineering, and Medicine.

To make the world safer against future infectious disease threats, national health systems should be strengthened, the World Health Organization’s emergency and outbreak response activities should be consolidated and bolstered, and research and development should be enhanced, says a new Policy Forum article that appears in the May 19 edition of PLOS Medicine.

At the May 2016 meeting of the CHR, James King, IIE-SRF Assistant Director, spoke to CHR members about IIE-SRF’s work, including its vital support of Syrian scholars during the 21st century’s worst humanitarian crisis.

Clinical trials for genome editing of the human germline – adding, removing, or replacing DNA base pairs in gametes or early embryos – could be permitted in the future, but only for serious conditions under stringent oversight, says a new report from the National Academy of Sciences and the National Academy of Medicine.